Get to know our clinical trials
Primer estudio en el ser humano de fase 1/2 sobre la seguridad y eficacia de IMC-F106C en monoterapia.
THE MAIN GOAL OF THIS STUDY IS TO FIND THE HIGHEST DOSE OF BMI-F106C THAT IS SAFE TO GIVE TO PEOPLE WITH ADVANCED CANCER, AND TO FIND OUT IF THIS DOSE CAN MAKE TUMORS STOP GROWING (OR SHRINK) AND IF CANCER PATIENTS CAN LIVE LONGER AND FEEL BETTER.
Technical Summary
- FIRST PHASE 1/2 HUMAN STUDY ON THE SAFETY AND EFFICACY OF BMI-F106C IN MONOTHERAPY AND IN COMBINATION WITH CHECKPOINT INHIBITORS IN PARTICIPANTS WITH HLA-A*02:01 EXPRESSING HLA-A*02:01 AND PRAME EXPRESSING ADVANCED CANCER
- Code EudraCT: 2019-004046-16
- Protocol number: IMC-F106C-101
- Promoter: Immunocore Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.